Quralis, a US-based precision therapeutics developer founded by Harvard University professors, has launched with an undisclosed amount of seed funding from investors including Amgen Ventures, a division of biopharmaceutical developer Amgen. The round included Alexandria Venture Investments, the corporate venturing arm of life science real estate developer Alexandria Real Estate Equities, and MP Healthcare Venture Management, part of Mitsubishi Tanabe Pharma Corporation, owned in turn by conglomerate Mitsubishi Chemical. Quralis hopes to exploit genetic research to develop therapeutics for amyotrophic lateral sclerosis (ALS), a group of paralysing motor neuron disorders that can leave patients with only two to five years to live. The company’s pipeline consists of treatments for three subtypes of ALS – a first drug aims to restore a dysfunctional cellular waste clearance system that poisons neurons, while a second therapy treats overactive neurons and prevents resulting cell death, and a third approach is meant to remove toxic proteins. Quralis is based on research by Harvard professors Kevin Eggan and Clifford Woolf. Eggan works in the Department of Stem Cell and Regenerative Biology at Harvard Stem Cell Institute, while Woolf is a professor of neurology and neurobiology at Harvard Medical School and the university-affiliated Boston Children’s Hospital. The pair co-founded Quralis alongside Jonathan Fleming, CEO of electrophysiology platform developer Q-State Biosciences, and Kasper Roet, a research fellow at Harvard’s Stem Cell Institute and Medical School who is now chief executive at Quralis.
Quralis steels itself for seed round
Apr 11, 2018 •
LEADERSHIP SOCIETY
Informing, connecting, and transforming the global corporate venture capital ecosystem.The Global Corporate Venturing (GCV) Leadership Society’s mission is to help bridge the different strengths and ambitions of investors across industry sectors, geography, structure, and their returns.
More featured content
Halo has researchers on speed dial for corporates
Halo has researchers on speed dial for corporates
How does a corporate find the right university researcher or startup when it's trying to solve a critical problem? Halo has the answer.
How Basel supercharged its spinout rate
How Basel supercharged its spinout rate
Basel has quietly built a life sciences ecosystem that’s becoming hard to ignore.
Crumbling system, fragile lives: can spinouts help in the senior care crisis?
Crumbling system, fragile lives: can spinouts help in the senior care crisis?
From a chest-worn device to help with Parkinson's symptoms to stress measuring socks — here are the spinouts providing support for senior citizens.
Events
Webinar: Innovate to heal - What does the hospital of the future look like?
Apr 10, 2024
Online
Online
Events
GCV Institute: Landing the Value of Corporate Venturing
May 6 -
May 9, 2024
Online
May 9, 2024
Online
Events
GCV Institute: CVC Investment Programs
May 21 -
May 22, 2024
Online
May 22, 2024
Online
Events
GCV Symposium 2024
Jun 24 -
Jun 26, 2024
London (UK)
Jun 26, 2024
London (UK)
Events
Corporate Venture in Brasil 2024 – International Delegation to Brazil
Oct 28 -
Oct 30, 2024
São Paulo (Brazil)
Oct 30, 2024
São Paulo (Brazil)
Top News
test reg